Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients

Phase 2

Terminated

Conditions: Hepatitis C

Interventions: Drug: LCQ908
Drug: Placebo

First Posted Date: 2011-07-06

Last Posted Date: 2012-05-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 32

Registration Number: NCT01387958

Locations: 🇳🇿
Novartis Investigative Site, Christchurch, New Zealand

A Study of BYL719 in Adult Patients With Advanced Solid Malignancies

Phase 1

Completed

Conditions: Advanced Solid Tumor

Interventions: Drug: BYL719

First Posted Date: 2011-07-04

Last Posted Date: 2020-12-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 33

Registration Number: NCT01387321

Locations: 🇯🇵
Novartis Investigative Site, Koto-ku, Tokyo, Japan

Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Phase 2

Completed

Conditions: Parkinson Disease
Parkinsonian Disorders
Dyskinesias
Movement Disorders

Interventions: Drug: Placebo
Drug: AFQ056

First Posted Date: 2011-06-30

Last Posted Date: 2020-12-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 78

Registration Number: NCT01385592

Locations: 🇪🇸
Novartis Investigative Site, San Sebastian, Spain

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Phase 2

Completed

Conditions: VEGF
Second-line Treatment
Solid Tumors and Advanced Endometrial Cancer
Endometrial Cancer

Interventions: Drug: TKI258

First Posted Date: 2011-06-23

Last Posted Date: 2015-05-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 53

Registration Number: NCT01379534

Locations: 🇺🇸
University of South Alabama / Mitchell Cancer Institute Univ South Alabama, Mobile, Alabama, United States
🇺🇸
St. Jude Heritage Medical Group St Jude, Fullerton, California, United States
🇺🇸
USC/Kenneth Norris Comprehensive Cancer Center USC 2, Los Angeles, California, United States

and more 19 locations

Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC

Phase 2

Terminated

Conditions: Hepatocellular Carcinoma

Interventions: Drug: everolimus placebo
Drug: everolimus

First Posted Date: 2011-06-23

Last Posted Date: 2017-05-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 65

Registration Number: NCT01379521

Locations: 🇹🇭
Novartis Investigative Site, Chiang Mai, Thailand

Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept

Phase 4

Completed

Conditions: Chronic Hepatitis B

Interventions: Drug: telbivudine
Drug: tenofovir disoproxil fumarate

First Posted Date: 2011-06-23

Last Posted Date: 2018-11-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 241

Registration Number: NCT01379508

Locations: 🇹🇷
Novartis Investigative Site, Trabzon, Turkey

Efficacy of Indacaterol 150 µg Versus Formoterol

Phase 4

Withdrawn

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: Indacaterol
Drug: Formoterol

First Posted Date: 2011-06-21

Last Posted Date: 2017-04-20

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT01377428

Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion

Phase 3

Completed

Conditions: Retinal Vein Occlusion

Interventions: Drug: ranibizumab

First Posted Date: 2011-06-21

Last Posted Date: 2016-11-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 47

Registration Number: NCT01377597

Locations: 🇯🇵
Novartis Investigative Site, Osaka, Japan

Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mg

Completed

Conditions: Cancer

Interventions: Drug: Nelarabine

First Posted Date: 2011-06-20

Last Posted Date: 2017-11-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 343

Registration Number: NCT01376115

Locations: 🇯🇵
University of Tsukuba Hospital, Tsukuba, Japan

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: Secukinumab (AIN457)
Biological: Placebo

First Posted Date: 2011-06-20

Last Posted Date: 2017-03-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 637

Registration Number: NCT01377012

Locations: 🇬🇧
Novartis Investigative Site, Salisbury, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy